CJC-1295 No DAC and Ipamorelin are two distinct synthetic peptides that appear together in some areas of laboratory research. Although they may be combined within a single research preparation, they are not the same molecule and should not be treated as interchangeable.
The key reason the combination is scientifically interesting is that the two compounds are associated with different signalling mechanisms. Understanding those differences is important when interpreting experimental literature or evaluating a combined research material.
This guide examines CJC-1295 No DAC and Ipamorelin from a laboratory research perspective, including their molecular roles, the meaning of “No DAC”, and important considerations when reviewing peptide blends.
What is CJC-1295 No DAC?
CJC-1295 No DAC is a synthetic peptide associated with research into growth hormone-releasing hormone (GHRH) receptor signalling.
The term No DAC indicates that the peptide does not contain the Drug Affinity Complex modification associated with a longer-duration CJC-1295 construct.
This distinction matters because adding or removing a structural modification can change the experimental characteristics of a peptide.
For a deeper explanation, read our CJC-1295 No DAC research overview.
What is Ipamorelin?
Ipamorelin is a synthetic peptide investigated in research relating to the ghrelin receptor, also known as the growth hormone secretagogue receptor (GHSR).
This distinguishes it mechanistically from CJC-1295 No DAC, which is associated with GHRH receptor signalling.
Although both peptides have appeared in research concerning growth-hormone-related signalling, they interact with different receptor systems.
CJC-1295 No DAC and Ipamorelin are separate research compounds. Their appearance within the same experimental preparation does not make them a single peptide.
CJC-1295 No DAC vs Ipamorelin
A useful way to understand the combination is to compare the two compounds directly.
| Characteristic | CJC-1295 No DAC | Ipamorelin |
|---|---|---|
| Compound | Synthetic peptide | Synthetic peptide |
| Primary research pathway | GHRH receptor signalling | Ghrelin receptor / GHSR signalling |
| Contains DAC? | No | Not applicable |
| Same molecule? | No | No |
Why are CJC-1295 No DAC and Ipamorelin researched together?
The scientific rationale for examining the two compounds together comes from their association with different receptor pathways within related endocrine signalling systems.
CJC-related peptides have been investigated through GHRH receptor pathways, while Ipamorelin has been studied through the ghrelin receptor.
This gives researchers an opportunity to investigate how separate signalling mechanisms behave individually and under combined experimental conditions.
Potential areas of laboratory investigation include:
- Peptide-receptor interactions
- GHRH receptor signalling
- Ghrelin receptor signalling
- Endocrine signalling pathways
- Structure-activity relationships
- Combined versus isolated experimental responses
These are research contexts and should not be interpreted as therapeutic claims.
Why does “No DAC” matter?
DAC stands for Drug Affinity Complex.
The DAC modification was developed to facilitate binding to albumin and thereby alter the experimental duration of a CJC-related peptide.
CJC-1295 No DAC does not contain this modification. Researchers should therefore distinguish between DAC and No DAC materials when reviewing literature, documenting experiments or comparing results.
Why composition matters in a peptide blend
A combined research preparation should clearly identify the amount of each component rather than presenting only a total quantity.
For example, BioTide UK's current CJC-1295 No DAC + Ipamorelin research blend contains:
- CJC-1295 No DAC — 5mg
- Ipamorelin — 5mg
- Total peptide content — 10mg
Recording individual component quantities is important because a total quantity alone does not describe the composition of a multi-component preparation.
What should researchers look for when evaluating a peptide blend?
1. Exact compound identity
Every component should be clearly identified. Similar names should not be assumed to represent identical molecules.
2. Individual component quantities
The quantity of each peptide should be stated rather than relying solely on the combined total.
3. Batch identification
Batch or lot information helps connect a physical research material with the relevant laboratory records and analytical documentation.
Read our guide to why batch testing matters for research peptides for more information about traceability.
4. Analytical methodology
Researchers should consider which analytical methods were used and what each method actually establishes.
Two techniques commonly encountered in peptide analysis are HPLC and mass spectrometry.
Our HPLC vs LC-MS peptide testing guide explains how these methods provide different types of analytical information.
5. Supporting documentation
Where batch-specific analytical documentation is available, researchers should check that the report corresponds to the relevant material and batch.
Available BioTide UK documentation can be reviewed in our analytical reports library.
What does HPLC tell researchers?
High-Performance Liquid Chromatography, or HPLC, separates components within a sample under defined analytical conditions.
In peptide analysis, chromatographic data can be used to evaluate the relative presence of the target material and other detectable components under the method used.
A reported HPLC purity value should therefore be interpreted within the context of the analytical method rather than treated as proof of every characteristic of a sample.
Researchers can learn more in our guide to reading an HPLC peptide report.
What does mass spectrometry tell researchers?
Mass spectrometry provides information relating to the mass-to-charge characteristics of molecules detected within a sample.
This can provide evidence relevant to molecular identity when the observed analytical data are compared with the expected characteristics of the target compound.
HPLC and mass spectrometry therefore provide different types of analytical information and can complement one another.
A headline purity percentage should not be viewed in isolation. Researchers should review the analytical method, compound identity, batch information and scope of the report.
Purity vs identity in a peptide blend
For multi-component preparations, analytical interpretation can be particularly important because more than one target compound is present.
A chromatographic purity result and evidence relating to molecular identity answer different analytical questions.
Researchers should therefore avoid assuming that one headline percentage completely characterises every component within a blend.
Our guide to what peptide purity actually means explains the difference between chromatographic purity, molecular identity and quantity.
What is a Certificate of Analysis for a peptide blend?
A Certificate of Analysis (COA) can present analytical information associated with a particular sample or batch.
For a blended peptide preparation, researchers should pay particular attention to how the report identifies the components, the methods used and the batch represented.
A COA should be interpreted according to the analytical evidence it actually contains rather than treated as a universal guarantee about every characteristic of the material.
Read our guide to peptide Certificates of Analysis for more information.
Why batch traceability matters
Traceability helps laboratories document exactly which materials were used within an experiment.
Useful records can include:
- Product name
- Individual components
- Quantity of each component
- Supplier
- Batch or lot identifier
- Date received
- Relevant analytical report
This becomes particularly important for blended research materials because more than one target compound is present within the same preparation.
Lyophilised peptide blends
Peptide blends may be supplied in lyophilised, or freeze-dried, form where specified.
Lyophilisation describes the controlled removal of water from frozen material under reduced-pressure conditions.
The term does not itself establish the identity, purity, quantity or stability of each peptide component.
Researchers can read our guide to what lyophilised means for a broader explanation.
Storage considerations for peptide blends
Storage requirements depend on the exact compounds, formulation, packaging and applicable technical documentation.
Researchers should follow the storage specifications provided for the particular blended material rather than assuming that all peptides or peptide blends require identical conditions.
Our guide to storing lyophilised research peptides covers the main laboratory considerations.
Frequently asked questions
Are CJC-1295 No DAC and Ipamorelin the same peptide?
No. They are distinct synthetic peptides associated with different receptor pathways.
What does CJC-1295 No DAC mean?
“No DAC” means that the CJC-related peptide does not contain the Drug Affinity Complex modification associated with the DAC-containing construct.
What receptor is associated with Ipamorelin research?
Ipamorelin has been investigated as an agonist of the ghrelin receptor, also called the growth hormone secretagogue receptor.
Why are CJC-1295 No DAC and Ipamorelin found in the same research blend?
The compounds are associated with distinct receptor pathways within related areas of endocrine research, making their combined experimental behaviour a subject of scientific interest.
How much is in BioTide UK's CJC-1295 No DAC + Ipamorelin blend?
The current BioTide UK research preparation contains 5mg CJC-1295 No DAC and 5mg Ipamorelin, giving 10mg total peptide content.
Does one purity percentage describe both peptides completely?
Not necessarily. In a multi-component preparation, researchers should review the analytical method and complete report to understand what was measured and how the individual components were evaluated.
Why does the batch number matter for a peptide blend?
A batch or lot identifier helps connect the physical blend with the analytical documentation representing the tested preparation.
Where can researchers view the product?
See the BioTide UK CJC-1295 No DAC + Ipamorelin research blend for the current product specification.
Final thoughts
CJC-1295 No DAC and Ipamorelin are separate synthetic research peptides associated with different receptor pathways. Their inclusion within the same research preparation makes exact identification, composition and batch traceability particularly important.
Researchers evaluating a peptide blend should look beyond the total quantity and consider the identity and amount of each component, the analytical methodology used and the documentation associated with the relevant batch.
Continue exploring with our CJC-1295 No DAC research guide, peptide purity guide, or batch-testing and traceability guide.
You can also view the CJC-1295 No DAC + Ipamorelin research blend, browse the BioTide UK research catalogue, or review available analytical reports.
Sources & further reading
Selected peer-reviewed literature relevant to growth hormone-releasing hormone analogues, ipamorelin and growth hormone secretagogue receptor biology. These references provide background on the individual research pathways rather than evidence for the combined preparation itself.
Published investigation of CJC-1295 providing background on synthetic growth hormone-releasing hormone analogue research.
Experimental research characterising ipamorelin and examining its selectivity within growth hormone secretagogue research.
Foundational research identifying ghrelin and providing biological context for the growth hormone secretagogue receptor pathway.
Learn more about how BioTide UK develops and maintains educational content: BioTide UK Research Team →
Related BioTide UK resources
Continue through related research materials, analytical documentation and laboratory resources.
CJC-1295 No DAC + Ipamorelin blend →Ipamorelin research material →View analytical reports →Explore the research range →
